- Tytuł:
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- Autorzy:
- Źródło:
- The Lancet; May 2019, Vol. 393 Issue: 10183 p1819-1830, 12p
Periodyk